Document is current

Article History

Received: 30 July 2025

Accepted: 20 November 2025

First Online: 27 November 2025

Declarations

:

: All analyses followed protocols approved by the Ethical Committee Bern (Project ID: 2019–00328). The study was performed in accordance with the Declaration of Helsinki. Patients qualified for inclusion in this study if they were informed about the conditions in the general consent and written general consent was signed. Inclusion also applied for patients whose prostate cancer tissue was collected prior to official use of general consent, and/or no written or documented verbal refusal was available at any time (Human Research Act, HRA, Swiss Confederation; Art. 34).

: According to the above mentioned ethical approval, we may publish the results after completion of the research project. Publications will not contain any references to specific individuals.

: Costs of FoundationOne®CDx analyses were covered by Roche Pharma (Schweiz) AG, Basel, Switzerland. D.A. has received honoraria for lectures, presentations or advisory boards from BMS, Janssen, and Bayer; conference/travel support from Janssen, Ipsen, and Bayer. H.M. has received research funding to University Zurich from F. Hoffmann-La Roche Ltd., and personal consultancy fees as advisory board member from Astra Zeneca and Stemline Therapeutics, Bayer, Amgen, Astella, MSD. M.A.R. is a co-inventor on patents in the area for diagnosis and therapy in prostate cancer for ETS fusions (University of Michigan and the Brigham and Women’s Hospital), SPOP mutations (Cornell University), and EZH2 (University of Michigan). The authors declare no competing interests.